Arthneeti

Tarsons Products Q1 FY27 Share Price & Earnings Call Analysis

₹291.00-4.26% today
Market cap
₹1,550 Cr
P/E
130.87
ROE
2.44%
Price to sales
3.50
Debt to equity
0.62
52W high / low
₹362 / ₹166
Sales growth (5Y)
13.04%
EBITDA margin
27.01%
Net profit margin
3.66%
Promoter holding
47.30%
Sales (last year)
₹441 Cr

Tarsons Products Ltd. (TPL) is an Indian labware company engaged in the designing, development, manufacturing, and marketing of 'consumables', 'reusables' and 'others' including benchtop equipment, used in various laboratories across research organizations, academia institutes, pharmaceutical companies, Contract Research Organizations, Diagnostic companies, and hospitals[1]

Guidance scorecard · Q1 FY27 call

What Tarsons Products Ltd's management guided
and where it ranks in Healthcare Equipment & Supplies

#10of 13 in
Healthcare Equipment & Supplies
Revenue10–20%MarginsFlatCapexPlannedFundraisingNone plannedOrder bookRising

RevenueQ1 FY27 call

10–20%
  • Tarsons expects sustainable revenue growth driven by expanded capacities and new product launches, particularly from FY’28 onwards.
  • Domestic market growth targeted at 15%+ year-on-year, with strong Q1 FY’27 performance exceeding 15% growth.
  • New Panchla and Amta facilities expected to contribute 20-25% of standalone revenues by FY’28.
  • Cell culture and other new product lines projected to generate approximately INR 65-70 crores in revenue in FY’28.
  • Exports showing a healthy recovery with 29% Y-o-Y growth in Q1 FY’27 and expected to be a key growth driver, especially through white-labeling.
  • Long-term growth anticipated from greater international presence and integration with Nerbe’s business, including improved product portfolio and geographical expansion.

2 more points from Tarsons Products Ltd's call on revenue

Create a free account to keep reading this call

Full Q1 FY27 analysis

MarginsQ1 FY27 call

Flat

See what Tarsons Products Ltd said on margins — free account, 30 seconds.

Full Q1 FY27 analysis

CapexQ1 FY27 call

Planned
  • Currently in final phase of large-scale capacity expansion program with significant CAPEX already commissioned and operational.
  • Remaining facility commissioning progressing as planned; trial runs underway; full commissioning expected during Q2 FY’27 with revenue contribution starting second half FY’27.
  • No major new CAPEX plans for this year besides maintenance; annual maintenance CAPEX expected around INR 20-25 crores.
  • Anticipate ramp-up revenues from new Panchla and Amta facilities contributing 20-25% to standalone revenues by FY’28.
  • Entire 4-year CAPEX plan expected to enable incremental revenue around INR 400 crores on fixed asset turnover basis, with peak sales potential around INR 750-800 crores.

2 more points from Tarsons Products Ltd's call on capex

Create a free account to keep reading this call

Full Q1 FY27 analysis

FundraisingQ1 FY27 call

None planned

See what Tarsons Products Ltd said on fundraising — free account, 30 seconds.

Full Q1 FY27 analysis

Order bookQ1 FY27 call

Rising
  • Export business inquiries are very promising and strong as long as the environment remains conducive to business.
  • Logistics, transportation, and input costs are currently major hurdles, more than tariffs.
  • The company experienced a significant benefit from shipments in the latest quarter, affecting revenue recognition, but shipment schedules remain beyond their control due to global logistic challenges.

2 more points from Tarsons Products Ltd's call on the order book

Create a free account to keep reading this call

Full Q1 FY27 analysis
Full Healthcare Equipment & Supplies ranking

Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.

Potential multibaggers · Q2 FY27

Potential multibaggers in Healthcare Equipment & Supplies
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Q-Line BiotechGood growth
    3
See all potential multibaggersWhere does Tarsons Products Ltd rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Healthcare Equipment & Supplies companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Flat₹627 Cr21.4
240%+Flat₹147 Cr16.8
3Q-Line Biotech20–40%Up 2%+₹1,467 Cr25.9
420–40%Flat₹18,144 Cr83.6
520–40%Flat₹173 Cr35.0
610–20%Up 2%+₹170 Cr18.8

Sign up free to see every company in the sector ranking and track Tarsons Products Ltd.

Pro shows every company guiding 40%+ revenue growth →Full Healthcare Equipment & Supplies ranking

Financials of Tarsons Products Ltd

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Tarsons Products Ltd

Quarterly Results

Quarter-by-quarter operating performance

Sep 2021Dec 2021Mar 2022Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales +76.0570.6684.9461.79105.7284.8099.2595.68112.6991.36102.33107.89120.93
Expenses +37.5837.5240.6138.9175.4866.0473.9466.0475.6766.6674.8876.3786.66
Operating Profit38.4733.1444.3322.8830.2418.7625.3129.6437.0224.7027.4531.5234.27
OPM %50.59%46.90%52.19%37.03%28.60%22.12%25.50%30.98%32.85%27.04%26.82%29.21%28.34%
Other Income +1.452.462.583.243.382.918.430.853.783.345.807.076.83
Interest1.561.370.452.514.254.324.845.035.205.075.186.056.25
Depreciation4.815.357.2410.0612.3311.0314.0317.4120.0319.9422.4825.0429.08
Profit before tax33.5528.8839.2213.5517.046.3214.878.0515.573.035.597.505.77
Tax %25.78%25.66%24.89%26.72%39.50%36.39%30.80%34.66%34.49%41.25%40.61%32.93%27.56%
Net Profit +24.9021.4729.469.9310.324.0210.295.2610.201.783.325.044.18
EPS in Rs4.894.045.541.871.940.761.930.991.920.330.620.950.79

Financials of Tarsons Products Ltd

Profit & Loss

Annual income statement trend

Mar 2021Mar 2022Mar 2024Mar 2025Mar 2026
Sales +229301296392423
Expenses +125148196282305
Operating Profit103153100111118
OPM %45%51%34%28%28%
Other Income +58111623
Interest34102023
Depreciation1422406297
Profit before tax92135614522
Tax %25%25%30%34%35%
Net Profit +69101433014
EPS in Rs3,583.2518.928.015.602.69
Dividend Payout %0%0%25%0%0%

Financials of Tarsons Products Ltd

Balance Sheet

Capital structure and asset base

Mar 2021Mar 2022Mar 2024Mar 2025Mar 2026
Equity Capital0.1911111111
Reserves244479602620624
Borrowings +3422269339393
Other Liabilities +183390111158
Total Liabilities2965449721,0801,186
Fixed Assets +120189336536733
CWIP2232267233159
Investments00000
Other Assets +153323369311295
Total Assets2965449721,0801,186

Financials of Tarsons Products Ltd

Cash Flows

Operating, investing and financing cash movement

Mar 2021Mar 2022Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +6883103114118
Cash from Investing Activity +-64-138-285-145-130
Cash from Financing Activity +-27130136399
Net Cash Flow-2375-478-3
Free Cash Flow6-48-81-37-7
CFO/OP89%77%121%117%107%

Financials of Tarsons Products Ltd

Ratios

Working capital efficiency and return ratios

Mar 2021Mar 2022Mar 2024Mar 2025Mar 2026
Debtor Days7579967474
Inventory Days277478572355341
Days Payable3575654453
Cash Conversion Cycle317482602385361
Working Capital Days108150-138-20
ROCE %35%7%5%

Guidance history

How Tarsons Products Ltd's guidance has moved, call by call

CallRevenueMarginsCapexFundraisingOrder book
Q1 FY27 call →10–20%FlatPlannedNone plannedRising
Q4 FY26 call →10–20%FlatNone plannedNone planned—
Q3 FY26 call →10–20%Up 0–2%Planned——
Q2 FY26 call →10–20%Up 2%+PlannedPlannedRising

What management guided on each call, newest first. Not investment advice, and not a forecast of returns.

34out of 100

Momentum score · price trend

34 out of 100 — Cooling

Over the past year its share price has done worse than most of the stocks we track.

PeriodShare price changeBetter than … of 1,910 stocks
Last 12 months+0.5%61%
Last 6 months+32.3%83%
Last 3 months−7.5%52%

The price is 66.6% below its all-time high of ₹871.1 (16 Sept 2022). Stocks more than 20% below their peak have their score halved, so 68 became 34.

How we calculate it

“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).

The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Tarsons Products Ltd: 0.4 × 61 + 0.4 × 83 + 0.2 × 52 = 68, halved to 34 because the price is more than 20% below its all-time high.

Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.

Full methodology →

This describes only how the share price has moved up to 30 Oct 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.

Continue your research

What Tarsons Products Ltd's management said in earlier quarters

Others in Healthcare Equipment & Supplies this season

  • Galaxy Medicare (Q2 FY27)

    Revenue from Operations (₹ Mn): . Key investor presentation takeaways from Galaxy Medicare's Q2 FY27 investor presentation — and how it ranks against sector pee

  • Nureca Ltd (Q2 FY27)

    Year-on-year growth in revenue from operations: approximately 55% increase (585.99 vs 378.41 million standalone) . Key results statement takeaways from Nureca's

  • Aprameya Engineering Ltd (Q2 FY26)

    H1FY26 Revenue from Operations: Rs 421.4 Mn, up 343% YoY from Rs 92.7 Mn in H1FY25. Key investor presentation takeaways from Aprameya Engineering Ltd's Q2 FY26

  • Nureca Ltd (Q2 FY26)

    Q2 FY26 Revenue from Operations: INR 528 million, a 7% year-on-year (YoY) growth from INR 493 million in Q2 FY25. Key investor presentation takeaways from Nurec

Compare:vs Poly Medicure Ltdvs Molbio Diagnostivs Sahajanand Medical Technologies Ltd